Molecular Oncology (Oct 2023)

Isocitrate dehydrogenase 1 sustains a hybrid cytoplasmic–mitochondrial tricarboxylic acid cycle that can be targeted for therapeutic purposes in prostate cancer

  • Kevin Gonthier,
  • Cindy Weidmann,
  • Line Berthiaume,
  • Cynthia Jobin,
  • Aurélie Lacouture,
  • Camille Lafront,
  • Mario Harvey,
  • Bertrand Neveu,
  • Jérémy Loehr,
  • Alain Bergeron,
  • Yves Fradet,
  • Louis Lacombe,
  • Julie Riopel,
  • Éva Latulippe,
  • Chantal Atallah,
  • Michael Shum,
  • Jean‐Philippe Lambert,
  • Frédéric Pouliot,
  • Martin Pelletier,
  • Étienne Audet‐Walsh

DOI
https://doi.org/10.1002/1878-0261.13441
Journal volume & issue
Vol. 17, no. 10
pp. 2109 – 2125

Abstract

Read online

The androgen receptor (AR) is an established orchestrator of cell metabolism in prostate cancer (PCa), notably by inducing an oxidative mitochondrial program. Intriguingly, AR regulates cytoplasmic isocitrate dehydrogenase 1 (IDH1), but not its mitochondrial counterparts IDH2 and IDH3. Here, we aimed to understand the functional role of IDH1 in PCa. Mouse models, in vitro human PCa cell lines, and human patient‐derived organoids (PDOs) were used to study the expression and activity of IDH enzymes in the normal prostate and PCa. Genetic and pharmacological inhibition of IDH1 was then combined with extracellular flux analyses and gas chromatography–mass spectrometry for metabolomic analyses and cancer cell proliferation in vitro and in vivo. In PCa cells, more than 90% of the total IDH activity is mediated through IDH1 rather than its mitochondrial counterparts. This profile seems to originate from the specialized prostate metabolic program, as observed using mouse prostate and PDOs. Pharmacological and genetic inhibition of IDH1 impaired mitochondrial respiration, suggesting that this cytoplasmic enzyme contributes to the mitochondrial tricarboxylic acid cycle (TCA) in PCa. Mass spectrometry‐based metabolomics confirmed this hypothesis, showing that inhibition of IDH1 impairs carbon flux into the TCA cycle. Consequently, inhibition of IDH1 decreased PCa cell proliferation in vitro and in vivo. These results demonstrate that PCa cells have a hybrid cytoplasmic–mitochondrial TCA cycle that depends on IDH1. This metabolic enzyme represents a metabolic vulnerability of PCa cells and a potential new therapeutic target.

Keywords